Our mission is to discover and develop new medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells.
The human body is a complex and heterogeneous system. Despite this, a century of biological discovery efforts have relied upon empirically optimized cell culture conditions that do not reflect this complexity. These conditions can mask metabolic adaptations that support the rapid proliferation of bacterial cells, lymphocyte populations, and cancer metastases.
Octagon's discovery platform can identify metabolic targets involved in these cellular adaptations. The company has developed a lead program that has shown activity against the highest priority bacterial “superbugs” in animal efficacy models. The approach has further been applied in targeting specific immunometabolic adaptations in select autoimmune indications. This represents a powerful new platform for identifying new ways to treat these devastating diseases.